Logo image of VERV

VERVE THERAPEUTICS INC (VERV) Stock Fundamental Analysis

USA - NASDAQ:VERV - US92539P1012 - Common Stock

11.13 USD
+0.03 (+0.27%)
Last: 7/24/2025, 8:09:50 PM
11.2 USD
+0.07 (+0.63%)
After Hours: 7/24/2025, 8:09:50 PM
Fundamental Rating

3

Taking everything into account, VERV scores 3 out of 10 in our fundamental rating. VERV was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VERV as it has an excellent financial health rating, but there are worries on the profitability. VERV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERV had negative earnings in the past year.
VERV had a negative operating cash flow in the past year.
VERV had negative earnings in each of the past 5 years.
VERV had a negative operating cash flow in each of the past 5 years.
VERV Yearly Net Income VS EBIT VS OCF VS FCFVERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

VERV has a Return On Assets of -29.47%. This is in the better half of the industry: VERV outperforms 67.09% of its industry peers.
VERV has a better Return On Equity (-38.23%) than 71.43% of its industry peers.
Industry RankSector Rank
ROA -29.47%
ROE -38.23%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-34.01%
ROE(3y)-34.07%
ROE(5y)-42.09%
ROIC(3y)N/A
ROIC(5y)N/A
VERV Yearly ROA, ROE, ROICVERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VERV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERV Yearly Profit, Operating, Gross MarginsVERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

VERV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERV has more shares outstanding
Compared to 5 years ago, VERV has more shares outstanding
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VERV Yearly Shares OutstandingVERV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VERV Yearly Total Debt VS Total AssetsVERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VERV has an Altman-Z score of 2.34. This is not the best score and indicates that VERV is in the grey zone with still only limited risk for bankruptcy at the moment.
VERV's Altman-Z score of 2.34 is fine compared to the rest of the industry. VERV outperforms 70.89% of its industry peers.
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.34
ROIC/WACCN/A
WACC9.04%
VERV Yearly LT Debt VS Equity VS FCFVERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

VERV has a Current Ratio of 9.84. This indicates that VERV is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 9.84, VERV is doing good in the industry, outperforming 78.12% of the companies in the same industry.
A Quick Ratio of 9.84 indicates that VERV has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.84, VERV is doing good in the industry, outperforming 78.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.84
Quick Ratio 9.84
VERV Yearly Current Assets VS Current LiabilitesVERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.48% over the past year.
Looking at the last year, VERV shows a very strong growth in Revenue. The Revenue has grown by 271.44%.
EPS 1Y (TTM)26.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.68%
Revenue 1Y (TTM)271.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%479.03%

3.2 Future

VERV is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.55% yearly.
VERV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.88% yearly.
EPS Next Y-8.2%
EPS Next 2Y-13.05%
EPS Next 3Y-5.63%
EPS Next 5Y-6.55%
Revenue Next Year93.9%
Revenue Next 2Y-7.98%
Revenue Next 3Y-9.91%
Revenue Next 5Y0.88%

3.3 Evolution

VERV Yearly Revenue VS EstimatesVERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
VERV Yearly EPS VS EstimatesVERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERV. In the last year negative earnings were reported.
Also next year VERV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERV Price Earnings VS Forward Price EarningsVERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERV Per share dataVERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

VERV's earnings are expected to decrease with -5.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.05%
EPS Next 3Y-5.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERVE THERAPEUTICS INC

NASDAQ:VERV (7/24/2025, 8:09:50 PM)

After market: 11.2 +0.07 (+0.63%)

11.13

+0.03 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners94.32%
Inst Owner Change-0.43%
Ins Owners5.16%
Ins Owner Change-8.43%
Market Cap992.13M
Revenue(TTM)59.61M
Net Income(TTM)-181006000
Analysts71.43
Price Target13.26 (19.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.98%
Min EPS beat(2)18.3%
Max EPS beat(2)47.66%
EPS beat(4)4
Avg EPS beat(4)24.6%
Min EPS beat(4)15.43%
Max EPS beat(4)47.66%
EPS beat(8)8
Avg EPS beat(8)20.65%
EPS beat(12)9
Avg EPS beat(12)11.75%
EPS beat(16)10
Avg EPS beat(16)-68.84%
Revenue beat(2)2
Avg Revenue beat(2)234.22%
Min Revenue beat(2)223.6%
Max Revenue beat(2)244.83%
Revenue beat(4)4
Avg Revenue beat(4)195.33%
Min Revenue beat(4)139.53%
Max Revenue beat(4)244.83%
Revenue beat(8)8
Avg Revenue beat(8)209.59%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.69%
PT rev (3m)-51.55%
EPS NQ rev (1m)-0.12%
EPS NQ rev (3m)-2.43%
EPS NY rev (1m)-1.93%
EPS NY rev (3m)8.61%
Revenue NQ rev (1m)3.49%
Revenue NQ rev (3m)-2.15%
Revenue NY rev (1m)13.96%
Revenue NY rev (3m)91.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.64
P/FCF N/A
P/OCF N/A
P/B 2.1
P/tB 2.1
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.67
BVpS5.31
TBVpS5.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.47%
ROE -38.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-34.01%
ROE(3y)-34.07%
ROE(5y)-42.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.21%
Cap/Sales 7.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.84
Quick Ratio 9.84
Altman-Z 2.34
F-Score4
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)232.67%
Cap/Depr(5y)247.65%
Cap/Sales(3y)257.49%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.68%
EPS Next Y-8.2%
EPS Next 2Y-13.05%
EPS Next 3Y-5.63%
EPS Next 5Y-6.55%
Revenue 1Y (TTM)271.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%479.03%
Revenue Next Year93.9%
Revenue Next 2Y-7.98%
Revenue Next 3Y-9.91%
Revenue Next 5Y0.88%
EBIT growth 1Y5.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.17%
EBIT Next 3Y-16.21%
EBIT Next 5YN/A
FCF growth 1Y3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.29%
OCF growth 3YN/A
OCF growth 5YN/A

VERVE THERAPEUTICS INC / VERV FAQ

What is the fundamental rating for VERV stock?

ChartMill assigns a fundamental rating of 3 / 10 to VERV.


Can you provide the valuation status for VERVE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to VERVE THERAPEUTICS INC (VERV). This can be considered as Overvalued.


How profitable is VERVE THERAPEUTICS INC (VERV) stock?

VERVE THERAPEUTICS INC (VERV) has a profitability rating of 1 / 10.